We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Riverside Acquires Portuguese Provider of Isolation and Cryopreservation of Stem Cells from Umbilical Cord Blood
News

Riverside Acquires Portuguese Provider of Isolation and Cryopreservation of Stem Cells from Umbilical Cord Blood

Riverside Acquires Portuguese Provider of Isolation and Cryopreservation of Stem Cells from Umbilical Cord Blood
News

Riverside Acquires Portuguese Provider of Isolation and Cryopreservation of Stem Cells from Umbilical Cord Blood

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Riverside Acquires Portuguese Provider of Isolation and Cryopreservation of Stem Cells from Umbilical Cord Blood"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Founded in 2003 by a group of young entrepreneurs with experience in the Portuguese healthcare industry, Crioestaminal gives the parents of newborn babies the opportunity to collect, isolate and cryopreserve umbilical cord blood stem cells. Today, more than 30,000 parents have entrusted Crioestaminal with the responsibility to save stem cells from their children.

If necessary, these cells can be used by the family to treat serious medical illnesses in the future since stem cells are the precursors to just about every type of specialized cell in the body and provide an unlimited supply of replacement tissues to help treat everything from diabetes to Parkinson's disease. These services are provided through public and private hospitals.

The worldwide market in stem-cell therapeutics is predicted to reach anywhere between EUR€ 6.8 billion to EUR€ 20.3 billion by 2015 and Crioestaminal, due to its first-mover advantage, earned reputation, and management experience will continue to play an important role in the future of the industry.

Advertisement